# A Phase 2 Study of Luvometinib Combined With Anlotinib in KRAS-mutated NSCLC

Source: https://onco.cc/trials/nct07562581/  
OnCo record `nct07562581` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Anlotinib in non-small-cell lung cancer, run by Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd., now recruiting.

## Summary

A Phase 2 Study of Luvometinib Combined With Anlotinib in KRAS-mutated NSCLC is a phase 2 interventional study registered as NCT07562581 by Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd., with 48 participants planned, started 2026-06-15 and due to reach its primary completion in 2029-06. Interventions recorded: luvometinib + anlotinib.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07562581
- Phase: 2
- Setting: A Multicenter, Open-label, Single-arm Phase 2 Study to Evaluate the Efficacy and Safety of Luvometinib Combined With Anlotinib in Patients With KRAS-mutated Metastatic Non-small Cell Lung Cancer
- Sponsor: Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
- Enrolled: 48

## Sources

- ClinicalTrials.gov NCT07562581: https://clinicaltrials.gov/study/NCT07562581

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- drugs: [Anlotinib](https://onco.cc/drugs/anlotinib/)
- companies: [Shanghai Fosun Pharmaceutical Industrial Development](https://onco.cc/companies/shanghai-fosun-pharmaceutical-industrial-development/)

---
JSON: https://onco.cc/api/v1/entities/nct07562581.json